Target: ₹3,350
CMP: ₹3,194.75
Dr Lal Path Labs delivered a beat on margins at 28.2 per cent. However, revenue was in-line while EBITDA/PAT delivered a slight beat by 4/5 per cent respectively. Overall revenue increased 11 per cent y-o-y to ₹600 crore with sample/patients volume growing 9/4 per cent y-o-y. The revenue per sample stood at ₹287 (+2.4 per cent y-o-y). This is primarily driven change in test mix as DLPL has not taken price hike. Swasthfit revenue contribution increased to 25 per cent in Q1-FY25 (vs 22/24 per cent in Q1-FY24/Q4-FY24).
EBITDA increased 16 per cent y-o-y/17 per cent q-o-q to ₹170 crore. Interestingly, EBITDA margin expanded 120 bps y-o-y/170 bps q-oq to 28.2 per cent. EBITDA per sample was ₹81 (+6 per cent y-o-y/6 per cent q-o-q). Adj. PAT was ₹100 crore (+29 per cent y-o-y/26 per cent q-o-q). Management expects growth to be volume-led complemented by change in test mix. Also, it continues to not take price-hike over the next 3-4 quarters. Moreover, it guided for EBITDA margins to be 26-27 per cent over the next 2-3 years.
We have reduced our earnings estimates for FY25 by 5 per cent and increased for FY26 by 2 per cent on the back of penetration into Tier-3/4 towns to drive volumes, Suburban becoming a dominant player in Mumbai market, Increasing contribution from Swasthfit offset by and higher opex.
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.